SILEXION THERAPEUTICS CORP Increase (Decrease) in Employee Related Liabilities
SILEXION THERAPEUTICS CORP (SLXN) reported Increase (Decrease) in Employee Related Liabilities of $68.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2026-08-14
- SILEXION THERAPEUTICS CORP increase (decrease) in employee related liabilities for the quarter ending 2026-06-30 was $68.00K, a 1600.00% increase year-over-year.
- SILEXION THERAPEUTICS CORP increase (decrease) in employee related liabilities for the quarter ending 2026-03-31 was -$319.00K.
- SILEXION THERAPEUTICS CORP increase (decrease) in employee related liabilities for the quarter ending 2025-12-31 was $158.00K.
- SILEXION THERAPEUTICS CORP increase (decrease) in employee related liabilities for the quarter ending 2025-09-30 was $93.00K, a 78.67% decline year-over-year.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $68.00K 10-Q · filed 2026-08-14 | -$251.00K 10-Q · filed 2026-08-14 | -$93.00K derived: sum of 3 quarters · filed 2026-08-14 | $0.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$319.00K S-1/A · filed 2026-08-10 | -$161.00K derived: sum of 2 quarters · filed 2026-08-10 | -$68.00K derived: sum of 3 quarters · filed 2026-08-10 | -$64.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $158.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $251.00K derived: sum of 2 quarters · filed 2026-08-10 | $255.00K derived: sum of 3 quarters · filed 2026-08-14 | $237.00K S-1/A · filed 2026-08-10 |
| 2025-09-30 | $93.00K 10-Q · filed 2025-11-12 | $97.00K derived: sum of 2 quarters · filed 2026-08-14 | $79.00K 10-Q · filed 2025-11-12 | $34.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $4.00K 10-Q · filed 2026-08-14 | -$14.00K 10-Q · filed 2026-08-14 | -$59.00K derived: sum of 3 quarters · filed 2026-08-14 | $377.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$18.00K S-1/A · filed 2026-08-10 | -$63.00K derived: sum of 2 quarters · filed 2026-08-10 | $373.00K derived: sum of 3 quarters · filed 2026-08-10 | $370.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | -$45.00K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-10 | $391.00K derived: sum of 2 quarters · filed 2026-08-10 | $388.00K derived: sum of 3 quarters · filed 2026-08-10 | $435.00K S-1/A · filed 2026-08-10 |
| 2024-09-30 | $436.00K 10-Q · filed 2025-11-12 | $433.00K derived: sum of 2 quarters · filed 2025-11-12 | $480.00K 10-Q · filed 2025-11-12 | $509.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$3.00K 10-Q · filed 2025-08-12 | $44.00K 10-Q · filed 2025-08-12 | $73.00K derived: sum of 3 quarters · filed 2025-08-20 | $60.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2024-03-31 | $47.00K 10-Q · filed 2025-05-13 | $76.00K derived: sum of 2 quarters · filed 2025-08-20 | $63.00K derived: sum of 3 quarters · filed 2025-08-20 | $43.00K derived: sum of 4 quarters · filed 2025-08-20 |
| 2023-12-31 | $29.00K derived: 8-K 12 month − 10-Q 9 month · filed 2025-08-20 | $16.00K derived: sum of 2 quarters · filed 2025-08-20 | -$4.00K derived: sum of 3 quarters · filed 2025-08-20 | -$46.00K 8-K · filed 2025-08-20 |
| 2023-09-30 | -$13.00K 10-Q · filed 2024-11-14 | -$33.00K derived: sum of 2 quarters · filed 2024-11-14 | -$75.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$20.00K 10-Q · filed 2024-08-29 | -$62.00K 10-Q · filed 2024-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |